Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 35-40

  Tourkantoni, Natalie ^a,c   Athanassiou Metaxa, Miranda ^a,b   Zafiriou, Dimitrios ^b   Tzimouli, Vassiliki ^b   Economou, Marina ^a,b   Taparkou, Antonia ^b   Perifanis, Vassilios ^a   Kanakoudi Tsakalidou, Florendia ^b  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Ag Sophia Children's Hospital   (Greece)

Author keywords

Thalassemia (thal); Combined chelation; Deferiprone (L1); Deferoxamine (DFO); Immunity; Neurophysiology

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DEFERIPRONE; DEFEROXAMINE; HISTONE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; SMOOTH MUSCLE ANTIBODY; THYROID ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; B LYMPHOCYTE; CHELATION THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNE STATUS; MONOTHERAPY; NERVE CONDUCTION; SCHOOL CHILD; T LYMPHOCYTE; THALASSEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AUTOANTIBODIES; B-LYMPHOCYTES; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; EVOKED POTENTIALS; FERRITINS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; T-LYMPHOCYTES;

EID: 39349086569     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701680631     Document Type: Conference Paper

References (11)

1. Del Vecchio G, Shettini F, Piacente L, De Santis A, Giordano P, De Mattia D. Effects of deferiprone on immune status and cytokine pattern in thalassemia major. Acta Haematol 2002; 108(3):144-149.
2. Pradhan V, Badakere S, Ghosh K. Antihistone and other autoantibodies in β-thalassemia major patients receiving iron chelators. Acta Haematol 2003; 109(1):35-39.
3. Zafeiriou D, Koussi A, Tsantali C, Kontopoulos E, Augoustidou P, Tsoubaris D, Athanassiou M. Neurophysiologic evaluation of long term desferrioxamine therapy in β-thalassemia patients. Pediatr Neurol 1998; 18(5):420-424.
4. Loebstein R, Dala I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser M, Koren G, Roifman C, Olivieri N. Immune function in patients with β thalassaemia receiving the orally active iron-chelating agent deferiprone. Br J Haematol 1997; 98(3):597-600.
5. Levine JE, Cohen A, MacQueen M, Martin M, Giardina PJ. Sensorimotor neurotoxicity associated with high dose deferoxamine treatment. J Pediatr Hematol Oncol 1997; 19(2):139-141.
6. Athanassiou-Metaxa M, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi-Tsakalidou F. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment. Acta Haematol 2003; 110(1):224-226.
7. Mehta J, Singhal S, Revankar R, Walvalkar A, Chablani A, Mehta BC. Fetal systemic lupus erythematosus in patient taking oral iron chelator L1. Lancet 1991; 337(8736):298.
8. Mehta J, Singhal S, Mehta BC. Oral iron chelator L1 and autoimmunity. Blood 1993; 81(1):1970-1971.
9. Berdoukas V, Bentley P, Frost H, Schnebli HP. Toxicity of oral iron chelator L1. Lancet 1993; 341(8852):1088.
10. Zafeiriou DI, Economou M, Athanassiou-Metaxa M. Neurological complications in β-thalassemia. Brain Dev 2006; 28(8):477-481.
11. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006; 91(2):1241-1243.